Genzyme Corporation / Biomatrix Inc.

Knee Osteoarthritis

Disease Overview

Knee osteoarthritis is a degenerative joint disease in which cartilage breakdown causes pain, stiffness, and loss of function. It disproportionately affects older adults and people with prior joint injury or obesity, and there are no disease-modifying drugs — management is symptomatic until joint replacement.

Competitive Landscape

The knee OA pain market in 2000 was dominated by oral NSAIDs (ibuprofen, naproxen), COX-2 inhibitors (Celebrex, Vioxx), acetaminophen, and intra-articular corticosteroid injections, with total knee arthroplasty as the end-stage option. Within viscosupplementation, Synvisc (hylan G-F 20, Biomatrix-marketed by Wyeth-Ayerst) competed with Hyalgan (Sanofi/Fidia) and Supartz (Smith & Nephew/Seikagaku), all positioned as cross-linked or linear hyaluronic-acid injections delivered as 3-5 weekly intra-articular shots. Synvisc differentiated on its higher-molecular-weight cross-linked hylan polymer, claiming longer joint-residence time. The Genzyme-Biomatrix deal mattered because it pulled Synvisc — the category-leading viscosupplement — inside an integrated biosurgery platform alongside Sepra adhesion-prevention products and Carticel autologous cartilage repair, letting Genzyme cross-sell to orthopedic surgeons and rheumatologists rather than rely on a Wyeth co-promotion. Subsequent Cochrane and AAOS reviews would label HA injections as having only modest benefit over placebo, pressuring the category, but at deal time Synvisc was a fast-growing franchise with >$100M in sales (per Genzyme 10-K filings). Source: https://en.wikipedia.org/wiki/Hyaluronic_acid